STEVEN GRANT DEEKS

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Roadblocks to translational challenges on viral pathogenesis
    Steven Deeks
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Nat Med 19:30-4. 2013
  2. pmc Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California
    Paulo Telles Dias
    Núcleo de Estudos e Pesquisas em Atenção ao Uso de Drogas NEPAD Universidade do Estado do Rio de Janeiro State University of Rio de Janeiro, 20940 200 Rio de Janeiro, RJ, Brasil
    BMC Infect Dis 11:208. 2011
  3. pmc Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
    Serena S Spudich
    Department of Neurology, University of California, San Francisco, USA
    BMC Infect Dis 5:98. 2005
  4. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  5. ncbi request reprint Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1
    Steven G Deeks
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    J Infect Dis 189:312-21. 2004
  6. ncbi request reprint Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
    Steven G Deeks
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    Blood 104:942-7. 2004
  7. pmc HIV infection, inflammation, immunosenescence, and aging
    Steven G Deeks
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, CA, USA
    Annu Rev Med 62:141-55. 2011
  8. ncbi request reprint Sustained CD4 responses after virological failure of protease inhibitor-containing therapy
    S G Deeks
    University of California and San Francisco General Hospital, San Francisco, California, USA
    Antivir Ther 4:7-11. 1999
  9. ncbi request reprint Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco 94110, USA
    J Infect Dis 192:1537-44. 2005
  10. ncbi request reprint Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients
    Steven G Deeks
    University of California, San Francisco General Hospital, San Francisco, CA 94110, USA
    Lancet 367:711-3. 2006

Detail Information

Publications74

  1. doi request reprint Roadblocks to translational challenges on viral pathogenesis
    Steven Deeks
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Nat Med 19:30-4. 2013
    ....
  2. pmc Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California
    Paulo Telles Dias
    Núcleo de Estudos e Pesquisas em Atenção ao Uso de Drogas NEPAD Universidade do Estado do Rio de Janeiro State University of Rio de Janeiro, 20940 200 Rio de Janeiro, RJ, Brasil
    BMC Infect Dis 11:208. 2011
    ..In the United States (U.S.) HCV GT 1 is reported as the most common infecting GT among chronically infected patients. In Europe, however, recent studies have suggested that the epidemiology of HCV GTs is changing...
  3. pmc Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
    Serena S Spudich
    Department of Neurology, University of California, San Francisco, USA
    BMC Infect Dis 5:98. 2005
    ..Because of its proximity to and shared barriers with the brain, cerebrospinal fluid (CSF) provides a useful window into and model of human CNS HIV infection...
  4. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  5. ncbi request reprint Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1
    Steven G Deeks
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    J Infect Dis 189:312-21. 2004
    ..Collectively, these data suggest that the selection of drug-resistance mutations may reduce the pathogenic potential of HIV, which leads to a balanced state of enhanced cellular immunity and low-level viremia...
  6. ncbi request reprint Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
    Steven G Deeks
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    Blood 104:942-7. 2004
    ..These data indicate that immunologic activation set point is established early in HIV infection, and that this set point determines the rate at which CD4+ T cells are lost over time...
  7. pmc HIV infection, inflammation, immunosenescence, and aging
    Steven G Deeks
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, CA, USA
    Annu Rev Med 62:141-55. 2011
    ..Novel therapeutic strategies aimed at preventing or reversing these immunologic defects may be necessary if HIV-infected patients are to achieve normal life span...
  8. ncbi request reprint Sustained CD4 responses after virological failure of protease inhibitor-containing therapy
    S G Deeks
    University of California and San Francisco General Hospital, San Francisco, California, USA
    Antivir Ther 4:7-11. 1999
    ..Observational clinical data of patients receiving protease inhibitor-based therapy who had a sustained CD4 cell count even with incomplete viral suppression will be presented, as well as possible mechanisms and clinical implications...
  9. ncbi request reprint Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco 94110, USA
    J Infect Dis 192:1537-44. 2005
    ..We hypothesized that the use of simplified regimens could maintain treatment benefit while preventing viral evolution and reducing drug-related toxicity and costs...
  10. ncbi request reprint Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients
    Steven G Deeks
    University of California, San Francisco General Hospital, San Francisco, CA 94110, USA
    Lancet 367:711-3. 2006
  11. pmc Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses
    Steven G Deeks
    Department of Medicine, University of California at San Francisco, San Francisco General Hospital, CA 94110, USA
    J Virol 80:6155-64. 2006
    ..These observations also suggest that the neutralizing antibody response may contribute to the long-term control of HIV in some patients while protecting against HIV superinfection in most patients...
  12. ncbi request reprint The risk of treatment versus the risk of HIV replication
    Steven G Deeks
    San Francisco General Hospital, San Francisco, California 94110, USA
    Lancet 367:1955-6. 2006
  13. pmc Antiretroviral treatment of HIV infected adults
    Steven G Deeks
    University of California, San Francisco and San Francisco General Hospital, San Francisco, CA 94110, USA
    BMJ 332:1489. 2006
  14. ncbi request reprint Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen
    Steven G Deeks
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Infect Dis 195:387-91. 2007
    ..Although enfuvirtide resistance mutations are associated with significant fitness defects in vivo, the clinical significance of these mutations remains undefined...
  15. pmc Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America
    Steven G Deeks
    University of California San Francisco, San Francisco, San Diego, CA 94110, USA
    Clin Infect Dis 49:1582-90. 2009
    ....
  16. ncbi request reprint Protease inhibitors as immunomodulatory drugs for HIV infection
    S G Deeks
    University of California, San Francisco, California, USA
    Clin Pharmacol Ther 82:248-50. 2007
    ..When used in combination, these drugs can lead to durable and perhaps indefinite suppression of viral replication...
  17. pmc Transmitted minority drug-resistant HIV variants: a new epidemic?
    Steven G Deeks
    University of California San Francisco, San Francisco, California, United States of America
    PLoS Med 5:e164. 2008
  18. ncbi request reprint Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate
    S G Deeks
    San Francisco General Hospital AIDS Program, University of California, San Francisco, California 94110, USA
    J Acquir Immune Defic Syndr 28:336-9. 2001
    ..05); however, the difference between the tenofovir and tenofovir plus hydroxyurea groups was not significant ( p =.90). We conclude that hydroxyurea does not significantly enhance the antiviral activity of low-dose tenofovir...
  19. ncbi request reprint Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
    S G Deeks
    University of California, San Francisco, and San Francisco General Hospital, USA
    N Engl J Med 344:472-80. 2001
    ..In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown...
  20. ncbi request reprint Determinants of virological response to antiretroviral therapy: implications for long-term strategies
    S G Deeks
    Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA
    Clin Infect Dis 30:S177-84. 2000
    ..Unfortunately, almost any factor (drug, host, or viral) that leads to virological failure of an initial combination regimen is likely to persist-and perhaps become more challenging-once a salvage regimen is initiated...
  21. ncbi request reprint CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy
    Steven G Deeks
    Department of Medicine, University of California at San Francisco and San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 185:315-23. 2002
    ..These data indicate that partial virus suppression reduces CD4(+) cell turnover and activation, thereby resulting in sustained CD4(+) cell gains, and that measurements of T cell dynamics may provide an in vivo marker of viral virulence...
  22. ncbi request reprint Treatment of antiretroviral-drug-resistant HIV-1 infection
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco, California 94110, USA
    Lancet 362:2002-11. 2003
    ....
  23. ncbi request reprint Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia
    Steven G Deeks
    UCSF AIDS Program, University of California and San Francisco General Hospital, San Francisco, California 94110, USA
    AIDS 16:201-7. 2002
    ..Sustained elevations in CD4 cell counts commonly occur despite incomplete viral suppression with protease inhibitor-based antiretroviral therapy...
  24. ncbi request reprint International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance
    S G Deeks
    San Francisco General Hospital, San Francisco, California and University of California, San Francisco, California, USA
    J Acquir Immune Defic Syndr 26:S25-33. 2001
    ..This article describes the scientific literature establishing the efficacy and limitations of NNRTI therapy and attempts to define a role for this class of drug in the long-term treatment of HIV-1 disease...
  25. ncbi request reprint Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response
    Steven G Deeks
    University of California San Francisco and San Francisco General Hospital, 995 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 17:361-70. 2003
    ..We therefore studied the long-term treatment outcome to antiretroviral therapy in a cohort of patients who had previously interrupted therapy, focusing on the determinants of treatment success versus failure...
  26. ncbi request reprint Supervised interruptions of antiretroviral therapy
    Steven G Deeks
    Positive Health Program, San Francisco General Hospital, University of California, San Francisco, 94110, USA
    AIDS 16:S157-69. 2002
  27. ncbi request reprint Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
    S G Deeks
    University of California, San Francisco, AIDS Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 181:946-53. 2000
    ..These observations suggest that transient or partial declines in plasma HIV RNA levels can have sustained effects on CD4+ T cell levels...
  28. ncbi request reprint Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia
    Annika C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
    AIDS 18:981-9. 2004
    ..The interaction of these factors is not well understood, particularly in the setting of antiretroviral therapy...
  29. pmc Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment
    Brinda Emu
    Department of Medicine, San Francisco General Hospital, University of California, 94110, USA
    J Virol 79:14169-78. 2005
    ....
  30. ncbi request reprint A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy
    Steven G Deeks
    University of California, San Francisco, California 94110, USA
    Mol Ther 5:788-97. 2002
    ..Both groups experienced a treatment-related increase in CD4(+) T-cell counts...
  31. ncbi request reprint A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  32. ncbi request reprint Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial
    Donald I Abrams
    University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA
    Ann Intern Med 139:258-66. 2003
    ..Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid-protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways)...
  33. ncbi request reprint Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals
    JoAnn C Castelli
    Department of Medicine and Department of Biostatistics, University of California, San Francisco 94143 1270, USA
    Blood 99:4225-7. 2002
    ..These data on CNAR in untreated, healthy, HIV-infected individuals support the current recommendation for when to initiate antiretroviral therapy...
  34. pmc Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, Department of Medicine, University of California, San Francisco, California, USA
    J Virol 76:11104-12. 2002
    ....
  35. ncbi request reprint High levels of adherence do not prevent accumulation of HIV drug resistance mutations
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, California, USA
    AIDS 17:1925-32. 2003
    ....
  36. ncbi request reprint A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide
    George Beatty
    University of California, San Francisco, CA, USA
    Antivir Ther 11:315-9. 2006
    ..The collective predictive activity of an enfuvirtide-containing regimen was important in predicting treatment response...
  37. pmc Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115
    Allan R Tenorio
    Department of Medicine, Rush Medical College, Rush University Medical Center, 600 S Paulina Street, Chicago, IL 60612, USA
    AIDS Res Hum Retroviruses 25:135-9. 2009
    ..Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters...
  38. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  39. pmc HIV-induced changes in T cell signaling pathways
    Marc Schweneker
    Division of Experimental Medicine, University of California, San Francisco, CA 94110, USA
    J Immunol 180:6490-500. 2008
    ....
  40. ncbi request reprint Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects
    Peter A Anton
    University of California, Los Angeles, the San Francisco General Hospital, San Francisco, California, USA
    AIDS 17:53-63. 2003
    ..To determine the levels of residual HIV DNA and RNA in blood and gut reservoirs in aviremic patients, assess correlations among compartmental measurements of HIV burden, and evaluate association with clinical parameters...
  41. ncbi request reprint Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 17:1907-15. 2003
    ..To determine the extent to which HIV-infected patients, including those with advanced immunodeficiency, can reverse peripheral CD4 T-cell depletion while maintaining long-term viral suppression on highly active antiretroviral therapy...
  42. pmc Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
    Elizabeth Sinclair
    Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 47:544-52. 2008
    ..To define the effect of antiretroviral therapy (ART) on activation of T cells in cerebrospinal fluid (CSF) and blood, and interactions of this activation with CSF HIV-1 RNA concentrations...
  43. pmc Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease
    David M Naeger
    Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e8886. 2010
    ..The impact of untreated and treated HIV infection on the frequency of these cells remains undefined...
  44. pmc The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy
    Michael Rosenblum
    Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 4:e7196. 2009
    ..We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression would decrease with longer duration of viral suppression...
  45. pmc HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses
    April L Ferre
    Department of Medical Microbiology and Immunology, School of Medicine, University of California, 3327 Tupper Hall, 1 Shields Ave, Davis, CA 95616, USA
    J Virol 84:11020-9. 2010
    ..43, P=0.005), suggesting that increased CD4+ T-cell "help" may be important in maintaining strong CD8+ T-cell responses in the gut of HIV controllers...
  46. pmc Loss of T cell responses following long-term cryopreservation
    Rachel E Owen
    Blood Systems Research Institute, 270 Masonic Avenue, San Francisco, CA 94118, USA
    J Immunol Methods 326:93-115. 2007
    ..Long-term cryopreservation, however, may lead to the loss of CD4(+) T cell responses and mild skewing of T cell phenotypic marker expression...
  47. ncbi request reprint Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease
    Christina M R Kitchen
    Department of Biostatistics, University of California, Los Angeles, Los Angeles, California 90095, Section of Retroviral Therapeutics, Brigham and Women s Hospital, Boston, MA 02115, USA
    AIDS Res Hum Retroviruses 22:1260-6. 2006
    ..In contrast to observations when all drugs are interrupted, loss of resistance during enfuvirtide interruption is most likely due to ongoing viral evolution (and back-mutation), rather than emergence of an archived virus...
  48. pmc History-adjusted marginal structural models for estimating time-varying effect modification
    Maya L Petersen
    Division of Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA
    Am J Epidemiol 166:985-93. 2007
    ....
  49. ncbi request reprint Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California, San Francisco, CA 94110, USA
    Circulation 109:1603-8. 2004
    ..HIV-infected patients may be at increased risk for coronary events. The purpose of this study was to identify predictors of carotid intima-media thickness (IMT) in HIV patients at baseline and to measure IMT progression over 1 year...
  50. pmc Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells
    Xavier Contreras
    Department of Medicine, University of California, San Francisco, California 94143, USA
    J Biol Chem 284:6782-9. 2009
    ..Thus SAHA, which is a Food and Drug Administration-approved drug, might be considered to accelerate the decay of the latent reservoir in HAART-treated infected humans...
  51. pmc Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease
    David Favre
    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, CA 94110, USA
    Sci Transl Med 2:32ra36. 2010
    ..We postulate that induction of IDO may represent a critical initiating event that results in inversion of the T(H)17/T(reg) balance and in the consequent maintenance of a chronic inflammatory state in progressive HIV disease...
  52. ncbi request reprint Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy
    Steven G Deeks
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 17:118-23. 2009
    ..This article summarizes a presentation made by Steven G. Deeks, MD, at the International AIDS Society-USA continuing medical education program in Chicago in May 2009...
  53. ncbi request reprint CD8 T cell effector maturation in HIV-1-infected children
    Kimberly A Jordan
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94158, USA
    Virology 347:117-26. 2006
    ..The data also suggest, however, that the perforin-deficient state of HIV-specific CD8 T cells in children may be reversible...
  54. pmc Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa
    Elvin H Geng
    Division of HIV AIDS, Department of Medicine, San Francisco General Hospital, San Francisco, CA, USA
    Trop Med Int Health 15:63-9. 2010
    ..Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality...
  55. pmc Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  56. pmc Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, California, USA
    AIDS 24:2535-9. 2010
    ..HAART can effectively reduce plasma HIV RNA levels to below the level of detection in most HIV-infected patients. The degree to which residual low-level viremia persists during HAART remains unclear...
  57. pmc Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers
    April L Ferre
    Dept of Medical Microbiology and Immunology, University of California, Davis, CA 95616, USA
    J Virol 84:10354-65. 2010
    ....
  58. ncbi request reprint Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, UCSF, San Francisco, California 94143 1372, USA
    AIDS 20:223-31. 2006
    ....
  59. ncbi request reprint Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital AIDS Program, University of California San Francisco, 94110, USA
    J Infect Dis 190:162-5. 2004
    ..Higher levels of viral suppression at 100% adherence (a marker of greater regimen potency) progressively reduce the overall population rate of drug resistance and shift the peak resistance rate to lower levels of adherence...
  60. ncbi request reprint T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Infect Dis 187:1534-43. 2003
    ..Interventions that directly target T cell activation or the determinants of activation may prove to be useful adjuvants to antiretroviral therapy...
  61. pmc When to start antiretroviral therapy
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA
    Curr HIV/AIDS Rep 7:60-8. 2010
    ..For patients who are motivated and willing to initiate early treatment, the collective benefits of early therapy may outweigh the well-documented risks of antiretroviral medications...
  62. pmc Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy
    Hiroyu Hatano
    University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 54:389-93. 2010
    ..Although integrase inhibitors are highly effective in the management of drug-resistant HIV, some patients fail to achieve durable viral suppression. The long-term consequences of integrase inhibitor failure have not been well defined...
  63. pmc HIV RNA level in early infection is predicted by viral load in the transmission source
    Frederick M Hecht
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, CA 94110, USA
    AIDS 24:941-5. 2010
    ..We sought to determine the relationship between HIV-1 RNA levels in the source partner and recently infected recipient partners within transmission pairs...
  64. ncbi request reprint Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco, CA 94110, USA
    Immunity 27:406-16. 2007
    ..Further understanding of the mechanisms whereby this occurs should yield critical insights for prophylactic and therapeutic antiviral interventions...
  65. pmc Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    Hiroyu Hatano
    San Francisco General Hospital, Building 80, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 83:329-35. 2009
    ..This confirms the failure to eradicate the virus, even in these unique individuals who are able to reduce plasma viremia to very low levels without antiretroviral therapy...
  66. pmc Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco and The Medical Service, San Francisco General Hospital, San Francisco, CA, USA
    PLoS ONE 4:e5277. 2009
    ....
  67. pmc Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, San Francisco, California 94110, USA
    AIDS 23:1059-67. 2009
    ....
  68. pmc Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients
    Priscilla Y Hsue
    Division of Cardiology, Positive Health Program of the Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 23:2021-7. 2009
    ..As endothelial dysfunction is central to the pathogenesis of atherosclerosis, we tested the hypothesis that current treatment with abacavir is associated with impaired endothelial function...
  69. pmc Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses
    Keith E Garrison
    Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California 94110, USA
    Clin Vaccine Immunol 16:1369-71. 2009
    ..T-cell responses to cryptic epitopes and to regions normally spliced out of the HIV-1 viral proteins Rev and Tat were detected in HIV-1-infected subjects...
  70. ncbi request reprint Adherence-resistance relationships to combination HIV antiretroviral therapy
    David R Bangsberg
    San Francisco General Hospital, UCSF, 1001 Potrero Avenue, Building 100, Room 301, San Francisco, CA 94110, USA
    Curr HIV/AIDS Rep 4:65-72. 2007
    ..Optimal antiretroviral regimens should be constructed such that there is little overlap in the window of adherence that selects for antiretroviral drug resistance...
  71. ncbi request reprint Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 194:926-30. 2006
    ..CCR5 inhibitors may thus be best strategically used before salvage therapy and before significant CD4 + T cell depletion...
  72. pmc HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy
    Andy I Choi
    Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    AIDS 23:2143-9. 2009
    ..To identify risk factors associated with kidney function decline in a contemporary cohort of treated and untreated HIV-infected patients...
  73. pmc HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers
    Peter W Hunt
    Department of Medicine, University of California, San Francisco, California, USA
    Clin Infect Dis 52:681-7. 2011
    ..Despite robust immune responses, these individuals never eradicate HIV infection. We hypothesized that HIV-specific CD4(+) T cells might serve as target cells for HIV, contributing to viral persistence in this setting...
  74. pmc A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers
    Peter W Hunt
    Departments of Medicine and Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e15924. 2011
    ..These data support a model in which low frequencies of Tregs in HIV controllers may contribute to an effective adaptive immune response, but may also contribute to generalized immune activation, potentially contributing to CD4 depletion...

Research Grants11

  1. The impact of early antiretroviral therapy on HIV persistence and inflammation
    STEVEN GRANT DEEKS; Fiscal Year: 2010
    ..Our work may also provide important insights in the role of chronic inflammation in driving viral persistence, and hence may lead to the development of novel interventions. ..
  2. Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir
    Steven Deeks; Fiscal Year: 2007
    ..Also, we believe that insights regarding the mechanisms operative in elite controllers will prove to be highly informative for future efforts aimed at preventing HIV infection and eradicating virus in those already infected. ..
  3. Immunologic Control of Drug-resistant HIV-1
    Steven Deeks; Fiscal Year: 2005
    ..Finally, since we will estimate the relative in vivo thresholds for HIV-mediated immunogenicity and pathogenicity, these studies may also have implications for vaccine development. ..
  4. Treatment Intensification for Drug-Resistant HIV
    Steven Deeks; Fiscal Year: 2004
    ..Funding for the pilot clinical trial has been obtained from other sources; funding is requested in this proposal only for costs associated with the measurements of immunologic response to drug-resistant HIV-1. ..
  5. The impact of early antiretroviral therapy on HIV persistence and inflammation
    STEVEN GRANT DEEKS; Fiscal Year: 2010
    ..Our work may also provide important insights in the role of chronic inflammation in driving viral persistence, and hence may lead to the development of novel interventions. ..